<p>即使一家公司在亏损，股东也有可能通过以合适的价格购买优质企业而获利。例如，尽管亚马逊在上市后的许多年里都在亏损，但如果你从 1999 年开始购买并持有其股票，你将赚得盆满钵满。然而，历史虽然赞美那些罕见的成功，但失败的案例往往被遗忘；谁还记得 Pets.com？</p>
<p>因此，<strong>NewAmsterdam Pharma</strong>（纳斯达克代码：NAMS）股东自然会问，是否应该担心其现金消耗率。在本文中，我们将现金消耗定义为其年度（负）自由现金流，即公司每年用于资助其增长的资金。我们将首先比较其现金消耗与现金储备，以计算其现金续航能力。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——仍然有机会提前投资。</p>
<h2>NewAmsterdam Pharma 的现金续航能力有多长？</h2>
<p>现金续航能力被定义为公司在保持当前现金消耗率的情况下，耗尽资金所需的时间。当 NewAmsterdam Pharma 在 2025 年 11 月最后一次报告其 2025 年 9 月的资产负债表时，它没有债务，现金价值为 7.03 亿美元。重要的是，其过去 12 个月的现金消耗为 1.45 亿美元。这意味着截至 2025 年 9 月，它的现金续航能力约为 4.9 年。然而，分析师认为 NewAmsterdam Pharma 将在此之前实现盈亏平衡（在自由现金流层面）。在这种情况下，它可能永远不会达到现金续航的尽头。你可以在下面的图像中看到其现金余额随时间的变化。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/685404834-debt-equity-history-analysis-1-dark-2/1766587950801?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/685404834-debt-equity-history-analysis-1-dark-2/1766587950801"/></p>
<p>纳斯达克 GM:NAMS2025 年 12 月 24 日的债务与股本历史</p>
<p>查看我们对 NewAmsterdam Pharma 的最新分析</p>
<h2>NewAmsterdam Pharma 的增长情况如何？</h2>
<p>NewAmsterdam Pharma 在过去一年中将现金消耗减少了 6.6%，这表明其在某种程度上具有一定的纪律性。运营收入也增长了 4.9%。考虑到上述数据，我们对业务增长轨迹相当乐观。然而，关键因素显然是公司未来是否会继续增长。因此，查看我们对该公司的分析师预测是非常有意义的。</p>
<h2>NewAmsterdam Pharma 筹集现金的难易程度如何？</h2>
<p>毫无疑问，NewAmsterdam Pharma 在管理其现金消耗方面似乎处于相对良好的位置，但即使这只是一个假设，询问它能多容易地筹集更多资金以资助增长也是值得的。发行新股或承担债务是上市公司为其业务筹集更多资金的最常见方式。许多公司最终会发行新股以资助未来的增长。我们可以将公司的现金消耗与其市值进行比较，以了解公司需要发行多少新股来资助一年的运营。</p>
<p>NewAmsterdam Pharma 的市值为 41 亿美元，去年消耗了 1.45 亿美元，占公司市值的 3.5%。这个比例较低，因此我们认为公司能够通过少量稀释筹集更多资金以资助增长，甚至可以简单地借一些钱。</p>
<h2>NewAmsterdam Pharma 的现金消耗情况有多风险？</h2>
<p>你可能已经意识到，我们对 NewAmsterdam Pharma 的现金消耗情况相对满意。特别是，我们认为其现金续航能力突显出公司对支出的良好控制。从这一分析来看，其现金消耗的减少是其最薄弱的特征，但我们对此并不担心。一个真正的积极因素是，分析师预测公司将实现盈亏平衡。综合考虑本文中的所有指标，我们对其现金消耗率并不担心；公司似乎很好地掌控了其中期支出需求。深入分析风险后，我们发现 <strong>NewAmsterdam Pharma 有一个警示信号</strong>，在投资前你应该注意。</p>
<p>当然，<strong>你可能会通过寻找其他地方找到一个绝佳的投资机会。</strong> 所以请查看这个 <strong>免费的</strong> 公司内部持股显著的名单，以及这个根据分析师预测的成长股名单。</p>
<p>用于国防和灾难的移动基础设施</p>
<p>下一波机器人技术不是人形的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随处可用。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>由 CiTech 赞助</p>

NAMS

<p>NewAmsterdam Pharma（纳斯达克代码：NAMS）截至 2025 年 9 月拥有 4.9 年的现金储备，现金为 7.03 亿美元，且没有债务。该公司将现金消耗减少了 6.6%，并将收入增加了 4.9%。分析师预测它将在耗尽现金储备之前实现盈亏平衡。该公司的市值为 41 亿美元，其现金消耗占其价值的 3.5%，这表明它可以以最小的稀释筹集资金。总体而言，该公司在管理现金消耗方面表现良好</p>

<p>Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?</p>
<div class="lb-trans"><p>即使一家公司在亏损，股东也有可能通过以合适的价格购买优质企业而获利。例如，尽管亚马逊在上市后的许多年里都在亏损，但如果你从 1999 年开始购买并持有其股票，你将赚得盆满钵满。然而，历史虽然赞美那些罕见的成功，但失败的案例往往被遗忘；谁还记得 Pets.com？</p>
</div><p>So, the natural question for <strong>NewAmsterdam Pharma</strong> (NASDAQ:NAMS) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.</p>
<div class="lb-trans"><p>因此，<strong>NewAmsterdam Pharma</strong>（纳斯达克代码：NAMS）股东自然会问，是否应该担心其现金消耗率。在本文中，我们将现金消耗定义为其年度（负）自由现金流，即公司每年用于资助其增长的资金。我们将首先比较其现金消耗与现金储备，以计算其现金续航能力。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——仍然有机会提前投资。</p>
</div><h2>How Long Is NewAmsterdam Pharma's Cash Runway?</h2>
<div class="lb-trans"><h2>NewAmsterdam Pharma 的现金续航能力有多长？</h2>
</div><p>A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. When NewAmsterdam Pharma last reported its September 2025 balance sheet in November 2025, it had zero debt and cash worth US$703m. Importantly, its cash burn was US$145m over the trailing twelve months. That means it had a cash runway of about 4.9 years as of September 2025. Notably, however, analysts think that NewAmsterdam Pharma will break even (at a free cash flow level) before then. In that case, it may never reach the end of its cash runway. You can see how its cash balance has changed over time in the image below.</p>
<div class="lb-trans"><p>现金续航能力被定义为公司在保持当前现金消耗率的情况下，耗尽资金所需的时间。当 NewAmsterdam Pharma 在 2025 年 11 月最后一次报告其 2025 年 9 月的资产负债表时，它没有债务，现金价值为 7.03 亿美元。重要的是，其过去 12 个月的现金消耗为 1.45 亿美元。这意味着截至 2025 年 9 月，它的现金续航能力约为 4.9 年。然而，分析师认为 NewAmsterdam Pharma 将在此之前实现盈亏平衡（在自由现金流层面）。在这种情况下，它可能永远不会达到现金续航的尽头。你可以在下面的图像中看到其现金余额随时间的变化。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/685404834-debt-equity-history-analysis-1-dark-2/1766587950801" alt="" original-src="https://images.simplywall.st/asset/chart/685404834-debt-equity-history-analysis-1-dark-2/1766587950801"/></p>
<p>NasdaqGM:NAMS Debt to Equity History December 24th 2025</p>
<div class="lb-trans"><p>纳斯达克 GM:NAMS2025 年 12 月 24 日的债务与股本历史</p>
</div><p>Check out our latest analysis for NewAmsterdam Pharma</p>
<div class="lb-trans"><p>查看我们对 NewAmsterdam Pharma 的最新分析</p>
</div><h2>How Well Is NewAmsterdam Pharma Growing?</h2>
<div class="lb-trans"><h2>NewAmsterdam Pharma 的增长情况如何？</h2>
</div><p>NewAmsterdam Pharma reduced its cash burn by 6.6% during the last year, which points to some degree of discipline. And operating revenue was up by 4.9% too. In light of the data above, we're fairly sanguine about the business growth trajectory. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.</p>
<div class="lb-trans"><p>NewAmsterdam Pharma 在过去一年中将现金消耗减少了 6.6%，这表明其在某种程度上具有一定的纪律性。运营收入也增长了 4.9%。考虑到上述数据，我们对业务增长轨迹相当乐观。然而，关键因素显然是公司未来是否会继续增长。因此，查看我们对该公司的分析师预测是非常有意义的。</p>
</div><h2>How Easily Can NewAmsterdam Pharma Raise Cash?</h2>
<div class="lb-trans"><h2>NewAmsterdam Pharma 筹集现金的难易程度如何？</h2>
</div><p>There's no doubt NewAmsterdam Pharma seems to be in a fairly good position, when it comes to managing its cash burn, but even if it's only hypothetical, it's always worth asking how easily it could raise more money to fund growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.</p>
<div class="lb-trans"><p>毫无疑问，NewAmsterdam Pharma 在管理其现金消耗方面似乎处于相对良好的位置，但即使这只是一个假设，询问它能多容易地筹集更多资金以资助增长也是值得的。发行新股或承担债务是上市公司为其业务筹集更多资金的最常见方式。许多公司最终会发行新股以资助未来的增长。我们可以将公司的现金消耗与其市值进行比较，以了解公司需要发行多少新股来资助一年的运营。</p>
</div><p>NewAmsterdam Pharma has a market capitalisation of US$4.1b and burnt through US$145m last year, which is 3.5% of the company's market value. That's a low proportion, so we figure the company would be able to raise more cash to fund growth, with a little dilution, or even to simply borrow some money.</p>
<div class="lb-trans"><p>NewAmsterdam Pharma 的市值为 41 亿美元，去年消耗了 1.45 亿美元，占公司市值的 3.5%。这个比例较低，因此我们认为公司能够通过少量稀释筹集更多资金以资助增长，甚至可以简单地借一些钱。</p>
</div><h2>How Risky Is NewAmsterdam Pharma's Cash Burn Situation?</h2>
<div class="lb-trans"><h2>NewAmsterdam Pharma 的现金消耗情况有多风险？</h2>
</div><p>It may already be apparent to you that we're relatively comfortable with the way NewAmsterdam Pharma is burning through its cash. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. On this analysis its cash burn reduction was its weakest feature, but we are not concerned about it. One real positive is that analysts are forecasting that the company will reach breakeven. Looking at all the measures in this article, together, we're not worried about its rate of cash burn; the company seems well on top of its medium-term spending needs. Taking an in-depth view of risks, we've identified <strong>1 warning sign for NewAmsterdam Pharma</strong> that you should be aware of before investing.</p>
<div class="lb-trans"><p>你可能已经意识到，我们对 NewAmsterdam Pharma 的现金消耗情况相对满意。特别是，我们认为其现金续航能力突显出公司对支出的良好控制。从这一分析来看，其现金消耗的减少是其最薄弱的特征，但我们对此并不担心。一个真正的积极因素是，分析师预测公司将实现盈亏平衡。综合考虑本文中的所有指标，我们对其现金消耗率并不担心；公司似乎很好地掌控了其中期支出需求。深入分析风险后，我们发现 <strong>NewAmsterdam Pharma 有一个警示信号</strong>，在投资前你应该注意。</p>
</div><p>Of course, <strong>you might find a fantastic investment by looking elsewhere.</strong> So take a peek at this <strong>free</strong> list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts)</p>
<div class="lb-trans"><p>当然，<strong>你可能会通过寻找其他地方找到一个绝佳的投资机会。</strong> 所以请查看这个 <strong>免费的</strong> 公司内部持股显著的名单，以及这个根据分析师预测的成长股名单。</p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用于国防和灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是人形的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随处可用。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 赞助</p>
</div>

我们对 Newamsterdam Pharma (NASDAQ:NAMS) 能否明智地使用其现金抱有希望